BioCorRx (BICX) Income from Continuing Operations (2010 - 2026)

BioCorRx has disclosed Income from Continuing Operations across 17 years of filings, most recently posting 859892.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 859892.0, down 0.95% year-over-year; the trailing twelve-month figure through Mar 2026 was 6554436.0 (down 35.8% YoY), and the FY2025 annual result was 3508763.0, up 32.68% from the prior year.
• Income from Continuing Operations came in at 859892.0 for Q1 2026 at BioCorRx, up from 3505936.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 811332.0 in Q3 2025 to a low of 3505936.0 in Q4 2025.
• The 5-year median for Income from Continuing Operations is 1010586.0 (2023), against an average of 1221181.94.
• Peak annual rise in Income from Continuing Operations reached 46.38% in 2025, while the deepest fall reached 185.59% in 2025.
• BioCorRx's Income from Continuing Operations stood at 1159792.0 in 2022, then grew by 16.45% to 969009.0 in 2023, then decreased by 26.69% to 1227633.0 in 2024, then plunged by 185.59% to 3505936.0 in 2025, then soared by 75.47% to 859892.0 in 2026.
• The last three Income from Continuing Operations figures came in at 859892.0 (Q1 2026), 3505936.0 (Q4 2025), and 811332.0 (Q3 2025), per Business Quant data.